Gene polymorphisms and pharmacogenetics in rheumatoid arthritis

Current Genomics

Volumn 9, Issue 6, 2008, Pages 381-393

  Rego Pérez, Ignacio ^a   Fernández Moreno, Mercedes ^a   Blanco, Francisco J ^a  

^a Osteoarticular and Aging Research Unit   (Spain)

Author keywords

Cytokines; Gene polymorphisms; IL 1; Pharmacogenomic; Rheumatoid arthritis; TNF

Indexed keywords

EID: 54749113733     PISSN: 13892029     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920208785699553     Document Type: Review

References (110)

1. Evans, W.E., Relling, M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286: 487-491.
2. Silman, A.J., MacGregor, A.J., Thomson, W., Holligan, S., Carthy, D., Farhan, A., Ollier, W.E. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br. J. Rheumatol. 1993, 32: 903-907.
3. Cornelis, F., Fauré, S., Martinez, M. Rheumatoid arthritis genome scan and pretative autoimmunity locus. Arthritis Rheum. 1997, 40: S329.
4. Pierik, M., Rutgeerts, P., Vlietinck, R., Vermeire, S. Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol. 2006, 12: 3657-3667.
5. Nepom, G.T. Major histocompatibility complex-directed susceptibility to rheumatoid arthritis. Adv. Immunol. 1998, 68: 315-332
6. Feldmann, M., Brennan, F.M., Maini, R.N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 1996, 14: 397-440.
7. Deighton, C.M., Walker, D.J., Griffiths, I.D., Roberts, D.F. The contribution of HLA to rheumatoid arthritis. Clin. Genet. 1989, 36: 178-182.
8. Gregersen, P.K., Silver. J, Winchester, R.J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987, 30: 1205-1213.
9. McGregor, A., Ollier, W., Thomson, W., Jawaheer, D., Silman, A. HLA-DRBI *0401/0404 genotype and rheumatoid arthritis: increased association in men, young age at onset, and disease severity. J. Rheumatol. 1995, 22: 1032-1036.
10. Reveille, J.D. Genetic studies in the rheumatic diseases: present status and implications for the future, J. Rheumatol. Suppl. 2005, 72: 10-13.
11. Martinez, A., Salido, M., Bonilla, G., Pascual-Salcedo, D., Fernandez-Arquero, M., de Miguel, S., de la Concha, E.G., Fernandez-Gutierrez, B. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum. 2004, 50: 1077-1082.
12. Padyukov, L., Lampa, J., Heimburger, M., Ernestam, S., Cederholm, T., Lundkvist, I., Andersson, P., Hermansson, Y., Harju, A., Klareskog, L., Bratt, J. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann. Rheum. Dis. 2003, 62: 526-529.
13. Brennan, F.M., Maini, R.N., Feldmann, M. TNF alpha -a pivotal role in rheumatoid arthritis? Br. J. Rheumatol. 1992, 31: 293-298.
14. Smith, C.A., Farrah, T., Goodwin, R.G. The TNF receptor super-family of cellular and viral proteins: activation, costimulation, and death. Cell 1994, 76: 959-962.
15. Vassalli, P. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 1992, 10: 411-452.
16. Verweij, C.L. Tumour necrosis factor gene polymorphisms as severity markers in rheumatoid arthritis. Ann. Rheum. Dis. 1999, 58: 120-126
17. Campbell, R.D., Trowsdale, J. (1993) Map of the human MHC. Immunol. Today 1993, 14: 349-352.
18. Wilson, A.G., de Vries, N., Pociot, F., di Giovine, F.S., van der Putte, L.B., Duff, G.W. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J. Exp. Med. 1993, 177: 557-560.
19. Jacob, C.O., Fronek, Z., Lewis, G.D., Koo, M., Hansen, J.A., McDevitt, H.O. Heritable major histocompatibility complex class II-associated differences in productioh of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 1990, 87: 1233-1237.
20. Brinkman, B.M., Huizinga, T.W., Kurban, S.S., van der Velde, E.A., Schreuder, G.M., Hazes, J.M., Breedyeld, F.C., Verweij, C.L. Tumour necrosk factor Alpha gene polymorphisms in rheumatoid arthritis. association with susceptibility to, or severity of disease. Br. J. Rheumatol. 1997, 36: 516-521.
21. Udalova, I.A., Richardson, A., Denys, A., Smith, C., Ackerman, H., Foxwell, B., Kwiatkowski, D. Functional consequences of a polymorphism affecting NF-kappaB p50-p50 binding to the TNF promoter region. Mol. Cell Biol.2000, 20: 9113-9119.
22. Newton, J., Brown, M.A., Milicic, A., Ackerman, H., Darke, C., Wilson, J.N., Wordsworth, B.P., Kwiatkowski, D. The effect of HLA-DR on susceptibility to rheumatoid arthritis is influenced by the associated lymphotoxin alpha-tumor necrosis factor haplotype. Arthritis Rheum. 2003, 48: 90-96.
23. Kuo, N.W., Lympany, P.A., Menezo, V., Lagan, A.L., John, S., Yeo, T.K., Liyanage, S., du Bois, R-M., Welsh, K.I., Lightman, S. TNF-857T, a genetic risk marker for acute anterior uveitis. Invest. Opthalmol. Vis. Sci. 2005, 46: 1565-1571.
24. Akman, A., Sallakci, N., Coskun, M., Bacanli, A., Yavuzer, U., Alpsoy, E., Yegin, O. TNF-alpha gene 1031 T/C polymorphism in Turkish patients with Behcet's disease. Br. J. Dermatol. 2006, 155: 350-356.
25. Smerdel, A., Lie, B.A., Ploski, R., Koeleman, B.P., Forre, O., Thorsby, E., Undlien, D.E. A gene in the telomeric HLA complex distinct from HLA-A is involved in predisposition to juvenile idiopathic arthritis. Arthritis Rheum. 2002, 46: 1614-1619.
26. Santee, S.M., Owen-Schaub, L.B. Human tumor necrosis factor receptor p75/ 80 (CD120b) gene structure and promoter characterization. J. Biol. Chem. 1996, 271: 21151-21159.
27. Ranganathan, P. Pharmacogenetics of tumor necrosis factor antagonists in rheumatoid arthritis. Pharmacogenomics 2005a, 6: 481-490.
28. Udalova, I.A., Nedospasov, S.A., Webb, G.C., Chaplin, D D., Turetskaya, R.L. Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics. 1993, 16: 180-186.
29. Mulcahy, B., Waldron-Lynch, F., McDermott, M.F., Adams, C., Amos, C.I., Zhu, D.K., Ward, R.H., Clegg, D.O., Shanahan, F., Molloy, M.G., O'Gara, F. Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis. Am. J. Hum. Genet. 1996, 59: 676-683.
30. van den Berg, W.B. Arguments for interleukin 1 as a target in chronic arthritis. Ann. Rheum. Dis. 2000, 59: 181-184.
31. Nicklin, M.J., Weith, A., Duff, G.W. A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics 1994, 19: 382-384.
32. Cox, A., Camp, N.J., Nicklin, M.J., di Giovine, F.S., Duff, G.W. An analysis of linkage disequilibrium in the interieukin-1 gene cluster, using a novel grouping method for multiallelic markers. Am. J. Hum. Genet. 1998, 62: 1180-1188.
33. McDowell, T.L., Symons, J.A., Ploski, R., Forre, O., Duff, G.W., A genetic association between juvenile rheumatoid arthritis and a novel interieukin-1 alpha polymorphism. Arthritis Rheum. 1995, 38: 221-228.
34. van den Velden, P.A., Reitsma, P.H. Amino acid dimorphism in IL1A is detectable by PCR amplification. Hum. Mol. Genet. 1993, 2: 1753.
35. di Giovine, F.S., Takhsh, E., Blakemore, A.I., Duff, G.W. Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta). Hum. Mol. Genet. 1992, 1: 450.
36. Pociot, F., Molvig, J., Wogensen, L., Worsaae, H., Nerup, J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur. J. Clin. Invest. 1992, 22: 396-402.
37. di Giovine, F.S., Camp, N.J., Cox, A. Detection and population analysis of IL-1 and TNF gene polymorphisms. 2000, In. Balkwill F (Ed.) Cytokine Molecular Biology. Oxford University Press, Oxford, pp. 21-46.
38. Cantagrel, A., Navaux, F,, Loubet-Lescoulie, P., Nourhashemi, F., Enault, G., Abbal, M., Constastin, A., Laroche, M., Mazières, B. Interleukin-1 beta, interleukin-1 receptor antagonist interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum. 1999, 42: 1093-1100.
39. Buchs, N., di Giovine, F.S., Silvestre, T., Vannier, E., Duff, G.W., Miossec, P. IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: interaction with their plasma levels. Genes Immun 2001, 2: 222-228.
40. Santtila, S., Savinainen, K., Hurme, M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand. J. Immunol. 1998, 47: 195-198.
41. Hulkkonen, J., Laippala, P., Hurme, M. A rare allele combination of the, interleukin-1 gene complex is associated with high interleukin-1 beta plasma levels in healthy individuals. Eur. Cytokine Netw. 2000, 11: 251-255.
42. Dominici, R., Cattaneo, M., Malferrari, G., Archi, D., Mariani, C., Grimaldi, L.M., Biunno, I. Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-2 alpha. Immunogenetics 2002, 54: 82-86.
43. Whyte, M., Hubbard, R., Meliconi, R., Whidborne, M., Eaton, V., Bingle, C., Timms, J., Duff, G., Facchini, A., Pacilli, A., Fabbri, M., Hall, I., Britton, J., Johnston, I., Di Giovine, F. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. Am. J. Respir. Crit. Care Med. 2000, 162: 755-758.
44. Feldmann, M., Brennan, F.M., Foxwell, B.M., Maini, R.N. The role of TNF alpha and IL-1 in rheumatoid arthritis. Curr. Dir. Autoimmun. 2001, 3: 188-199.
45. Uson, J., Balsa, A., Pascual-Salcedo, D., Cabezas, J.A., Gonzalez-Tarrio, J.M., Martín-Mola, E., Fontan, G. Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J. Rheumatol. 1997, 24: 2069-2075.
46. Xing, Z., Gauldie, J., Cox, G., Baumann, H., Jordana, M., Lei, X.F., Achong, M.K. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. 1998, 101: 311-320.
47. Tilg, H., Trehu, E., Atkins, M.B., Dinarello, C.A., Mier, J.W. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994, 83: 113-118.
48. Pascual, M., Nieto, A., Mataran, L., Balsa, A., Pascual-Salcedo, D., Martin, J. IL-6 promoter polymorphisms in rheumatoid arthritis. Genes Immun. 2000, 1: 338-340.
49. Fishman, D., Faulds, G., Jeffery, R., Mohamed-Ali, V., Yudkin, J.S., Humphries, S., Woo, P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 1998, 102: 1369-1376.
50. Martinez, A., Pascual, M., Pascual-Salcedo, D., Balsa, A., Martin, J., de la Concha, E.G. Genetic polymorphisms in Spanish rheumatoid arthritis patients: an association and linkage study. Genes Immun. 2003, 4: 117-121.
51. Chernoff, A.E., Granowitz, E.V., Shapiro, L., Vannier, E., Lonnemann, G., Angel, J.B., Kennedy, J.S., Rabson, A.R., Wolff, S.M., Dinarello, C.A. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J. Immunol. 1995, 154: 5492-5499.
52. Turner, D.M., Williams, D.M., Sankaran, D., Lazarus, M., Sinnott, P.J., Hutchinson, I.V. An investigation of polymorphism in the interleukin-10 gene promoter. Eur. J. Immunogenet. 1997, 24: 1-8.
53. Braun, N., Michel, U., Ernst, B.P., Metzner, R., Bitsch, A., Weber, F., Rieckmann, P. Gene polymorphism at position -308 of the tumor-necrosis-factor-alpha (TNF-alpha) in multiple sclerosis and it's influence on the regulation of TNF-alpha production. Neurosci. Lett. 1996, 215: 75-78.
54. Padyukov, L., Hytonen, A.M., Smolnikova, M., Hahn-Zoric, M., Nilsson, N., Hanson, L.A., Tarkowski, A., Klareskog, L. Polymorphism in promoter region of IL-10 gene is associated with rheumatoid arthritis in women. J. Rheumatol. 2004, 31: 422-425.
55. Moreno, O.M., González, C.I., Saaibi, D.L., Otero, W., Badillo, R., Martín, J., Ramírez, G. Polymorphisms of IL-10 gene promoter and rheumatoid arthsitis in a Colombian population. Biomedica 2007, 27: 56-65.
56. Dervieux, T., Brenner, T.L., Hon, Y.Y., Zhou, Y., Hancock, M.L., Sandlund, J.T., Rivera, G.K., Ribeiro, R.C., Boyett, J.M., Pui, C.H., Relling, M.V., Evans, W.E. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood 2002, 100: 1240-1247.
57. Kremer, J.M. Toward a better understanding of methotrexate [review]. Arthritis Rheum. 2004, 50: 1370-1382.
58. Dervieux, T., Lein, D.O., Park, G., Barham, R., Smith, K., Walsh, M. Single nucleotide polymorphisms (SNPs) in the folate/purine synthesis pathway predict methotrexate's effect in rheumatoid arthritis. Arthritis Rheum. 2003, 48: S438.
59. Pawlik, A., Wrzesniewska, J., Fiedorowicz-Fabrycy, I., Gawronska-Szklarz, B. The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int. J. Clin. Pharmacol. Ther. 2004, 42: 496-503.
60. Kang, S.S., Zhou, J., Wong, P.W., Kowalisyn, J., Strokosch, G. Intermediate homocysteinemia: A thermolabile variant of methylenetetrahydrofolate reductase. Am. J. Hum. Genet. 1998, 43: 414-421.
61. Haagsma, C.J., Blom, H.J., van Riel, P.L., van't Hof, M.A., Giesendorf, B.A., van Oppenraaij-Emmerzaal, D., van de Putte, L.B. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann. Rheum. Dis. 1999, 58: 79-84.
62. Urano, W., Taniguchi, A., Yamanaka, H., Tanaka, E., Nakajima, H., Matsuda, Y., Akama, H., Kitamura, Y., Kamatani, N. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002, 12: 183-190
63. Taniguchi, A., Urano, W., Tanaka, E., Furihata, S., Kamitsuji, S., Inoue, E., Yamanaka, M., Yamanaka, H., Kamatani, N. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet. Genom. 2007, 17: 383-390.
64. Dervieux, T., Greenstein, N., Kremer, J. Pharmacogenetic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 2006, 54: 3095-3103.
65. Berkun, Y., Levartovsky, D., Rubinow, A., Orbach, H., Aamar, S., Grenader, T., Abou Atta, L, Mevorach, D., Friedman, G., Ben-Yehuda, A. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann. Rheum. Dis. 2004, 63: 1227-1231.
66. Kumagai, K., Hiyama, K., Oyama, T., Maeda, H., Cono, N. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Intl. J. Mol. Med. 2003, 11: 593-600.
67. Wessels, J.A., van der Kooij, S.M., le Cessie, S., Kievit, W., Barerra, P., Allaart C.F., Huizinga, T.W., Guchelaar, H.J. Pharmacogenetics Collaborative Research Group. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 2007, 56: 1765-1775.
68. Herrlinger, K.R., Cummings, J.R., Barnardo, M.C., Schaw, M., Ahmad, T., Jewell, D.P. The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenet. Genom. 2005, 15: 705-711.
69. Horie, N., Aiba, H., Oguro, K., Hojo, H., Takeishi, K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 1995, 20: 191-197.
70. DiPaolo, A., Chu, E. The role of thymidylate synthase as a molecular biomarker. Clin. Cancer Res. 2004, 10: 411-412.
71. Ulrich, C.M., Bigler, J., Velicer, C.M., Greene, E.A., Farin, F.M., Potter, J.D. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol. Biomarkers Prev. 2000, 9: 1381-1385.
72. Grzybowska, E.A., Wilczynska, A, Siedlecki, J.A. Regulatory functions of 3ÚTRs. Biochem. Biophys. Res. Commun. 2004, 288: 291-295.
73. Dervieux, T., Furst, D., Lein, D.O., Capps, R., Smith, K., Walsh, M., Kremer, J. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 2004, 50: 2766-2774.
74. Rains, C.P., Noble, S., Faulds, D. Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 1995, 50: 137-156.
75. Pullar, T., Capell, H.A. (1986) Variables affecting efficacy and toxicity of sulphasalazine in rheumatoid arthritis. A review. Drugs 1986, 32: 54-57.
76. Wadelius, M., Stjemberg, E., Wiholm, B.E., Rane, A. Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis. Pharmacogenetics 2000, 10: 35-41.
77. Tanaka, E., Taniguchi, A., Urano, W., Nakajima, H., Matsuda, Y., Kitamura, Y., Saito, M., Yamanaka, H., Saito, T., Kamatani, N. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J. Rheumatol. 2002, 29: 2492-2499.
78. Ranganathan, P. Pharmacogenetics of therapies in rheumatoid arthritis. Drugs Today 2005b, 41: 799-814.
79. Krynetski, E.Y., Tai, H.L., Yates, C.R., Fessing, M.Y., Loennechen, T., Schuetz, J.D., Relling, M.V., Evans, W.E. Genetic polymorphism of thiopurine S-methyltransferase: Clinical importance and molecular mechanisms. Pharmacogenetics 1996, 6: 279-290.
80. Tai, H.L., Krynetsky, E.Y., Schuetz, E.G., Yanishevsky, Y., Evans, W.E. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): Mechanisms for the genetic polymorphism of TPMT activity. Proc. Natl. Acad. Sci. USA 1997, 94: 6444-6449.
81. Corominas, H., Domènech, M., Laiz, A., Gich, I., Gell, C., Diaz,, C., de Cuevillas, F., Moreno, M., Vázquez, G., Baiget, M. Is thiopurine methyltransferase genetic polymorphism a major factor for withdrawal of azathioprine in rheumatoid arthritis patients? Rheumatology 2003, 42: 40-45.
82. Genovese, M.C., Bathon, J.M., Martin, R.W., Fleischmann, R.M., Tesser, J.R., Schiff, M.H., Keystone, E.C., Wasko, M.C., Moreland, L.W., Weaver, A.L., Markenson, J., Cannon', G.W., Spencer-Green, G., Finck, B.K. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum. 2002, 46: 1443-1450.
83. Keystone, E.C., Kavanaugh, A.F., Sharp, J.T., Tannenbaum, H., Hua, Y., Teoh, L.S., Fischkoff, S.A., Chartash, E.K. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004, 50: 1400-1411.
84. Greenberg, J.D., Ostrer, H. The promise of pharmacogenetics to TNF antagonists in rheumatoid arthritis. Bull. NYU Hosp. Joint Dis. 2004, 65: 139-142.
85. Ferraccioli, G. The possible clinical application of pharmacogenetics in rheumatology. J. Rheumatol. 2003, 30: 2517-2520.
86. Lipsky, P.E., van der Heijde, D.M., St Clair, E.W., Furst, D.E., Breedveld, F.C., Kalden, JR., Smolen, J.S., Weisman, M., Emery, P., Feldmann, M., Harriman, G.R., Maini, R.N., Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 2000, 343: 1594-1602.
87. Bouma, G., Crusius, J.B., Oudkerk Pool, M., Kolkman, J.J., von Blomberg, B.M., Kostense, P.J., Giphart, M.J., Schreuder, G.M., Meuwissen, S.G., Peña, A.S. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand. J. Immunol. 1996, 43: 456-463.
88. Callan, M.F. Epstein-Barr virus, arthritis, and the development of lymphoma in arthritis patients. Curr. Opin. Rheumatol. 2004, 16: 399-405.
89. Mohan, N., Edwards, E.T., Cupps, T.R., Oliverio, P.J., Sandberg, G., Crayton, H., Richert, J.R., Siegel, J.N. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001, 44: 2862-2869.
90. Baecklund, E., Ekbom, A., Sparen, P., Feltelius, N., Klareskog, L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998, 317: 180-181.
91. Emery, P., van de Putte, L.B.A., van Riel, P.L.C.M., Rau, R., Schattenkirchner, M., Burmester, G.R. Changes in Pro-MMP-1 in relation to standard measures of disease activity over a 6-month treatment period with adalimumab (D2E7) in rheumatoid arthritis. Arthritis Rheum. 2001, 44: 215.
92. Bresnihan, B., Alvaro-Gracia, J.M., Cobby, M., Doherty, M., Domljan, Z., Emery, P., Nuki, G., Pavelka, K., Rau, R., Rozman, B., Watt, I., Williams, B., Aitchison, R., McCabe, D., Musikic, P. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998, 41: 2196-2204.
93. Cohen, S., Hurd, E., Cush, J., Schiff, M., Weinblatt, M.E., Moreland, L.W., Kremer, J., Bear, M.B., Rich, W.J., McCabe, D. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002, 46: 614-624.
94. Fleischmann, R.M., Schechtman, J., Bennett, R., Handel, M.L., Burmester, G.R., Tesser, J., Modafferi, D., Poulakos, J., Sun, G. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 2003, 48: 927-934.
95. Criswell, L.A., Lum, R.F., Turner, K.N., Woehl, B., Zhu, Y., Wang, J., Tiwari, H.K., Edberg, J.C., Kimberly, R.P., Moreland, L.W., Seldin, M.F., Bridges, S.L. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004, 50: 2750-2756.
96. Walsh, E.C., Mather, K.A., Schaffner, S.F., Farwell, L., Daly, M.J., Patterson, N., Cullen, M., Carrington, M., Bugawan, T.L., Erlich, H., Campbell, J., Barrett, J., Miller, K., Thomson, G., Lander, E.S., Rioux, J.D. An integrated haplotype map of the human major histocompatibility complex. Am. J. Hum. Genet. 2003, 73: 580-590.
97. Kang, C.P., Lee, K.W., Yoo, D.H., Kang, C., Bae, S.C. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford) 2005, 44: 547-552.
98. Fabris, M., Tolusso, B., Di Pol, E., Assaloni, R., Sinigaglia, L., Ferraccioli, G. Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. J. Rheumatol. 2002, 29: 1847-1850.
99. Schotte, H., Schluter, B., Drynda, S., Willeke, P., Tidow, N., Assmann, G., Domschke, W., Kekow, J., Gaubitz, M. Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2005, 64: 575-581.
100. Mugnier, B., Balandraud, N., Darque, A., Roudier, C., Roudier, J., Reviron, D. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum. 2003, 48: 1849-1852.
101. Cuchacovich, M., Ferreira, L., Aliste, M., Soto, L., Cuenca, J., Cruzat, A., Gatica, H., Schiattino, I., Pérez, C., Aguirre, A., Salazar-Onfray, F., Aguillón, J.C. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand. J. Rheumatol. 2004, 33: 228-232.
102. Fonseca, J.E., Carvalho, T., Cruz, M., Nero, P., Sobral, M., Mourao, A.F., Cavaleiro, J., Ligeiro, D., Abreu, I., Carmo-Fonseca, M., Branco, J.C. Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Ann. Rheum. Dis. 2005, 64: 793-794.
103. Pinto, J.A., Rego, I., Fernandez López, C., Freire, M., Fernández Sueiro, J.L., Blanco, F.J., Rodríguez-Gómez, M., Sanmartí, R., Cañete, J.D. Polymorphisms in genes encoding TNF-alpha and HLA-DRB1 are not associated with response to infliximab in patients with rheumatoid arthritis. J. Rheumatol. 2008, 35(1): 177-178
104. Camp, N.J., Cox, A., di Giovine, F.S., McCabe, D., Rich, W., Duff, G.W. Evidence of a pharmacogenomic response to interleukin-1 receptor antagonist in rheumatoid arthritis. Genes Immun. 2005, 6: 467-471.
105. Arnett, F.C., Edworthy, S.M., Bloch, D.A., McShane, D.J., Fries, J.F., Cooper, N.S., Healey, L.A., Kaplan, S.R., Liang, M.H., Luthra, H.S., Thomas A. Medsger, T.A., Mitchell, D.M., Neustadt, D., Pinals, R.S., Schaller, J.G., Sharp, J.T., Wilder, R.L., Hunderet G. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324.
106. Choy, E.H., Panayi, G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 2001, 344: 907-916.
107. Bridges, S.L. The genetics of rheumatoid arthritis: influences on susceptibility, severity, and treatment response. Curr. Rheumatol. 1999, 1: 164-171.
108. Evans, W.E., McLeod, H.L. Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 2003, 348: 538-549.
109. Lequerré, T., Gauthier-Jauneau, A.C., Bansard, C., Derambure, C., Hiron, M., Vittecoq, O., Daveau, M., Mejjad, O., Daragon, A., Tron, F., Le Loët, X., Salier, J.P. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res. Ther. 2006, 8: R105
110. Hirschhorn, J.N., Lohmueller, K., Byrne, E., Hirschhorn, K.A. A comprehensive review of genetic association studies. Genet. Med. 2002, 4: 45-61.